IQVIA Holdings Inc. (IQV)
NYSE: IQV · Real-Time Price · USD
180.34
-6.48 (-3.47%)
Jun 2, 2026, 2:00 PM EDT - Market open
IQVIA Holdings Revenue
IQVIA Holdings had revenue of $4.15B in the quarter ending March 31, 2026, with 8.41% growth. This brings the company's revenue in the last twelve months to $16.63B, up 7.32% year-over-year. In the year 2025, IQVIA Holdings had annual revenue of $16.31B with 5.87% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+7.32%
P/S Ratio
1.87
Revenue / Employee
$178,839
Employees
93,000
Market Cap
30.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.31B | 905.00M | 5.87% |
| Dec 31, 2024 | 15.41B | 421.00M | 2.81% |
| Dec 31, 2023 | 14.98B | 574.00M | 3.98% |
| Dec 31, 2022 | 14.41B | 536.00M | 3.86% |
| Dec 31, 2021 | 13.87B | 2.52B | 22.14% |
| Dec 31, 2020 | 11.36B | 271.00M | 2.44% |
| Dec 31, 2019 | 11.09B | 676.00M | 6.49% |
| Dec 31, 2018 | 10.41B | 710.00M | 7.32% |
| Dec 31, 2017 | 9.70B | 2.89B | 42.36% |
| Dec 31, 2016 | 6.82B | 1.08B | 18.79% |
| Dec 31, 2015 | 5.74B | 277.00M | 5.07% |
| Dec 31, 2014 | 5.46B | 360.45M | 7.07% |
| Dec 31, 2013 | 5.10B | 234.04M | 4.81% |
| Dec 31, 2012 | 4.87B | 537.76M | 12.43% |
| Dec 31, 2011 | 4.33B | 403.73M | 10.29% |
| Dec 31, 2010 | 3.92B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 14.14B |
| Quest Diagnostics | 11.28B |
| Agilent Technologies | 7.23B |
| IDEXX Laboratories | 4.45B |
| Illumina | 4.39B |
| Mettler-Toledo International | 4.09B |
| Waters | 3.77B |
| Revvity | 2.90B |
IQV News
- 6 days ago - IQVIA CEO to Speak at Jefferies Global Healthcare Conference - Business Wire
- 19 days ago - Iqvia, Kexing expand strategic collaboration - TheFly
- 19 days ago - IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities - Business Wire
- 20 days ago - IQVIA Holdings Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Iqvia approves $2B increase to share repurchase authorization - TheFly
- 25 days ago - IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization - Business Wire
- 25 days ago - Iqvia price target lowered to $225 from $240 at Morgan Stanley - TheFly
- 26 days ago - IQVIA CFO to Speak at Bank of America Health Care Conference 2026 - Business Wire